Significant Accounting Policies - Additional Information (Details) - USD ($)						3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 28, 2023	Jan. 14, 2022	Oct. 12, 2021	Mar. 19, 2021	Jan. 25, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2022	Oct. 04, 2021
Schedule Of Significant Accounting Policies [Line Items]
Accounts receivable from revenue with customers outstanding						$ 0		$ 0
Upfront nonrefundable payment					$ 1,000,000
Reimbursement payment				$ 14,000,000
Expected term of stock option granted to employees and directors, average contractual term and vesting period								10 years
Collaboration agreement amount				25,000,000
Development payments				10,000,000
Deferred collaboration funding	$ 4,500,000
Deferred collaboration funding, current											$ 8,412,971
Cash in excess of FDIC insured limit						300,000		$ 300,000			2,100,000
Income tax expense (benefit)						0	$ 0	0	$ 0
Uncertain tax positions, accruals						0		0			0
Accruals for interest or penalties related to income tax matters						0		0			0
Payments to collaboration partner	7,000,000					$ 6,952,802		$ 6,952,802
ASU No. 2016-13
Schedule Of Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]						true		true
Change in Accounting Principle, Accounting Standards Update, Adoption Date						Mar. 31, 2023		Mar. 31, 2023
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]						true		true
Accounts Payable and Accrued Expenses
Schedule Of Significant Accounting Policies [Line Items]
Preclinical or clinical study expense						$ 1,600,000		$ 1,600,000			$ 900,000
Maximum
Schedule Of Significant Accounting Policies [Line Items]
Cash, FDIC insured amount						$ 250,000		$ 250,000
Relief Therapeutics Holding AG
Schedule Of Significant Accounting Policies [Line Items]
Upfront payment	10,000,000
Loss contract termination	7,000,000
Relief Therapeutics Holding AG | Termination of Collaboration Agreement
Schedule Of Significant Accounting Policies [Line Items]
Upfront payment	10,000,000
Additional payment due on first year anniversary of upfront payment	$ 1,500,000
Percentage of royalty on net sales	10.00%
Percentage of revenue from certain third parties related to licensing	20.00%
Termination of collaboration and license agreement, cap price	$ 45,000,000
Maximum payment for licensing or divestment rights	56,500,000
Relief Therapeutics Holding AG | Accrued Payment to Collaboration Partner
Schedule Of Significant Accounting Policies [Line Items]
Additional payment on first-year anniversary of upfront payment	$ 1,500,000
Collaboration Agreement | Relief Therapeutics Holding AG
Schedule Of Significant Accounting Policies [Line Items]
Cash payment received				10,000,000						$ 10,000,000
Reimbursement payment				14,000,000	$ 14,000,000
Repayment of promissory note of prior loan and interest				$ 4,000,000
Net profit split ratio based on territory				60.00%	60.00%
Percentage of royalty net sales received				15.00%
Milestone payment to be received				$ 6,000,000	$ 6,000,000
Proceeds from development payments subject to acceptance of new drug application												$ 10,000,000
Development and commercialization services and reliefs right of profit percentage				60.00%
Percentage of payment net profit territory				60.00%
Upfront non-refundable payment received					$ 1,000,000
Development payments				$ 20,000,000
Collaboration Agreement | Relief Therapeutics Holding AG | Secured Loan
Schedule Of Significant Accounting Policies [Line Items]
Debt instrument, term					12 months
Debt instrument, principal amount					$ 4,000,000
Debt instrument, interest rate					6.00%
Collaboration Agreement | Relief Therapeutics Holding AG | Maximum
Schedule Of Significant Accounting Policies [Line Items]
Development payments					$ 20,000,000
Waiver and Agreement | Relief Therapeutics Holding AG | Second Development Payment
Schedule Of Significant Accounting Policies [Line Items]
Proceeds from first tranche of development payments subject to new drug application			$ 5,000,000
Proceeds from second tranche of development payments subject to new drug application		$ 5,000,000
Collaboration and License Agreement
Schedule Of Significant Accounting Policies [Line Items]
Upfront non-refundable payment received				$ 1,000,000
Collaboration and License Agreement | Relief Therapeutics Holding AG | Secured Loan
Schedule Of Significant Accounting Policies [Line Items]
Debt instrument, term					12 months
Debt instrument, principal amount					$ 4,000,000
Debt instrument, interest rate					6.00%
Exclusive License Agreement | Relief Therapeutics Holding AG | Maximum
Schedule Of Significant Accounting Policies [Line Items]
Percentage of right to receive royalty on net sales	10.00%